Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01308619 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo
A Phase 4 study, sponsored by Galderma R&D.
- Completed
- Registry status
- Phase 4
- Development phase
- 170
- Enrollment target
NCT01308619 is a Phase 4 study that has completed, run by Galderma R&D. The registered enrollment target is 170 participants.
The verdict
NCT01308619, a Phase 4 study, has completed, sponsored by Galderma R&D.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 170 participants
- Enrollment target
Study Summary
The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related inflammatory markers.
Interventions
- OTHER Placebo
- DRUG Doxycycline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2011-04 |
| Est. Completion | 2012-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01308619
The ClinicalTrials.gov registry entry for NCT01308619 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01308619 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01308619 about?
NCT01308619 is a clinical study titled "Evaluation of Rosacea-related Inflammatory Biochemical Markers in Adult Skin When Treated With Oracea® vs Placebo". The objective of this study is to determine the clinical effects of doxycycline 40 mg (30 mg immediate release and 10 mg delayed release beads) capsules (Oracea®) as compared to placebo in the skin of adults with papulopustular rosacea and to identify a correlation, if any, with rosacea-related infl...
What is the current status of trial NCT01308619?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 170 participants. The study started on 2011-04. Estimated completion is 2012-08.
What interventions are being tested in trial NCT01308619?
The interventions under investigation include: Placebo (OTHER), Doxycycline (DRUG).
Who is sponsoring clinical trial NCT01308619?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.